|
CIRKULIRAJUĆI
NIVOI PROLAKTINA U ODNOSU NA ŽIVOTNU DOB U BOLESNICA SA RAKOM DOJKE CILJ: U cilju što svrsishodnijeg vrjednovanja kliničke upotrebljivosti prolaktina (PRL) u bolesnica sa rakom dojke, njegovi cirkulirajući nivoi su usporedjivani sa starosnom dobi kao pokazateljom koji sam po sebi može mijenjati tok bolesti. ISPITANICI I METODE: Glavnu ispitivanu skupinu je činilo 47 bolesnica u kojih je dijagnoza raka dojke bila histološki potvrdjena. Korištene su dvije kontrolne skupine: klinički zdrave žene (40), i bolesnice sa malignim tumorima različitog histološkog porijekla i lokalizacije (33). Pacijentice iz obje skupine sa rakom bile su dalje podijeljene u podskupine prema njihovim razinama PRL i starosnoj dobi. PRL je mjeren radioimunoesejom u svim slučajevima. Rezultati su statistički obradjeni uz pomoć t-testa i logističkih linearnih modela sa izračunavanjem Pearsonovog koeficijenta korelacije. REZULTATI: Cirkulirajući nivoi PRL prije liječenja, kao i učestalost njihovih povišenih nivoa, bili su značajno viši u bolesnica sa rakom dojke u odnosu na obje kontrolne skupine (P<0,01; P<0,02). Cirkulirajući nivoi PRL bili su značajno viši (P<0,001) u bolesnica sa rakom dojke, a koje su bile starije od 45 godina, u odnosu na one mladje od 45 godina. Ista razlika je uočena kada su usporedjivane bolesnice sa rakom dojke, a koje su bile starije od 50 godina i one mladje od 50 godina (P<0,01), dok razlike nije bilo izmedju onih starijih od 55 i onih mladjih od 55 godina. Ovakve razlike nisu uočene medju bolesnicama sa ostalim malignim tumorima. Nije postojala značajna korelacija izmedju PRL i životne dobi u bolesnica sa rakom dojke , a kada su one bile podijeljene u podskupine: hiper, normo i hipoprolaktinemičnih. ZAKLJUČCI: Dobiveni rezultati ukazuju na postojanje rizične starosne dobi (izmedju 45 i 55 godina života) za nastajanje hiperprolaktinemije u bolesnica sa rakom dojke.
AIM: With the aim of the most appropriate evaluation of clinical usefullness of prolactin (PRL) in breast cancer patients (BCP), its circulating levels have been compared with the age in BCP, as a parameter which by itself can modify the course of disease. SUBJECTS AND METHOD: The main experimental group consisted of 47 female patients with histologically confirmed diagnosis of BC. Two control groups have been used: apparently clinically healthy women (40), and female patients with other locations of cancer (33). Patients in both cancer groups were further divided according to their levels of PRL and their age into appropriate subgroups. All measurements of PRL were performed by means of immumoradiometric assay. Results were processed by means of t-test, and logistic general linear models with calculation of Pearson's coefficient confirmed by the use of Shapiro-Wilk and probability plot methods. RESULTS: The circulating levels of PRL before treatment as well as the frequency of their elevated levels were significantly higher in BCP in comparison to controls (P<0.01, and P< 0.02). The circulating levels of PRL in BCP who were older than 45 years were significantly higher than in those who were younger than 45 years (P<0.001). The same difference was observed between BCP patients older and younger than 50 years (P<0.01), but was not observed when BCP were divided into those older than 55, and those younger than 55 years (P<0.1). Such a difference was not observed in patients with other cancers. There was not a statistically significant correlation between PRL levels and age when patients were divided in subgroups of hyper, normo and hypoprolactinemic. CONCLUSIONS: These results suggest that there is an age high risk group (between 45 and 55 years) for hyperprolactinemia in BCP. After 55 years of age this disease become less aggressive. |
|
|
| HOME PAGE |
